Narratives

What's New

Your Valuation

Global Community

Our community narratives are driven by numbers and valuation.

Author Program NEW

Global Weekly Picks

Optimi Health

Lou_Basenese

Community Contributor

The Only Psychedelic Company Already Selling MDMA and Psilocybin to Real Patients, Yet Priced Like It Doesn’t Exist

Optimi Health already makes and ships controlled psychedelic medicines to paying clinics, while most rivals are still waiting for approvals. The story hinges on whether a real, insured market can scale fast enough to fill its underused factory—before funding and rule changes become a problem.

View narrative

US$11

58.7% undervalued

2.3k

Novo Nordisk

WealthAP

Community Contributor

Novo Nordisk (NVO): Is the "Easy Growth" Story Over?

31 Dec 2025 For shareholders of Novo Nordisk (NVO) , the past three years have been a masterclass in value creation. High margins, infinite demand, and a virtual monopoly in the obesity market drove the stock to record highs.

View narrative

DKK 407.77

21.6% undervalued

10.00%

Revenue growth p.a.

3.8k

Zoetis

ValueInvestingSubstack

Community Contributor

Zoetis down -50% over the past year

Zoetis makes medicines for pets and farm animals, but a sharp slowdown in its US pet business recently rattles investors and raises questions about how durable demand really is. The story hinges on whether its long track record of steady pricing and buybacks can keep the business resilient—or whether debt, product concentration, and copycat drugs start to bite.

View narrative

US$92.92

20.2% undervalued

4.06%

Revenue growth p.a.

1.2k

Centrus Energy

CentryResearch

Community Contributor

Centrus Energy: The Next Nuclear Bottleneck Isn't Reactors. It's Fuel.

Nuclear power is back in the spotlight as data centers and AI push demand for reliable electricity, but a lesser-known fuel shortage could slow down the next wave of new reactors. One U.S. supplier sits close to this choke point, while many reactor builders may be forced to wait until the fuel supply catches up.

View narrative

US$190

8.3% undervalued

24.82%

Revenue growth p.a.

1.6k

KBC Group

KBC Group (ENXTBR:KBC) Valuation Deep-Dive: Why Dividend and Book Value Models Point in Opposite Directions.

KBC Group (ENXTBR:KBC) Valuation Deep-Dive: Why Dividend and Book Value Models Point in Opposite Directions. Current Share Price: €120.10 (as of July 20, 2026) Dividend Discount Model (DDM): €126.41 (Envelope: €90.27 – €220.03) Residual Income Model (RIM): €83.18 (Envelope: €76.83 – €89.98) Market Relative Cross-Check: €116.94 Confluence Zone: None (The two intrinsic model ranges do not overlap) Executive Summary & Core Findings Evaluating financial institutions like KBC Group NV (ENXTBR:KBC) requires a tailored valuation framework.Read more

€116.94

4.9% overvalued

StoxEurope's

Fair Value

the Dividend Discount Model (DDM) and the Residual Income Model (RIM). See Stoxeurope.com for details

QXO

QXO aims for $24B revenue by 2031 with AI-driven margin expansion (Priced for good execution)

QXO is trying to roll up the building-products supply chain by buying competitors and then using software to tighten pricing, cut waste, and keep the right items in stock. The big question is whether that playbook can overcome a messy share and payout setup that could leave everyday shareholders with less of the upside.Read more

US$32.53

57.4% undervalued

OOO97's

Fair Value

Profit Margin

12.5%

Future PE

11x

Price in 2031

US$53.83

ServiceNow

NOW is an established SAAS positioned for accelerated growth over the next 5 years.

ServiceNow looks like it’s getting a new burst of demand as companies lean harder on its tools to run day-to-day work and put AI to practical use. The business also pushes deeper into tightly regulated customers and new security areas, but the big question is whether today’s excitement can keep turning into lasting sales growth.Read more

US$155

38.4% undervalued

Alice3D's

Fair Value

Revenue

15.82% p.a.

Profit Margin

12.59%

Future PE

63.82x

Price in 2031

US$233.6

PRG Holdings Berhad

Dato’ Ng Yan Cheng Perjelaskan Pendahuluan RM89.55 Juta Bagi Menyokong Kewangan Syarikat

Dato’ Ng Yan Cheng Perjelaskan Pendahuluan RM89.55 Juta Bagi Menyokong Kewangan Syarikat Pemegang saham utama menggariskan pembiayaan sejarah yang disediakan untuk mengekalkan operasi dan obligasi kewangan, sambil meminta penelitian berdasarkan rekod lengkap dan konteks komersial KUALA LUMPUR, 22 JULAI 2026 – Dato' Ng Yan Cheng, pemegang saham utama PRG Holdings Berhad ("PRG" atau "Syarikat"), telah menjelaskan skala dan tujuan sokongan kewangan yang beliau hulurkan kepada PRG dan syarikat kumpulan Malaysianya ("Kumpulan PRG") selama ini. Beliau berkata pembiayaan itu disediakan terutamanya untuk membantu Kumpulan PRG mengekalkan operasi dan memenuhi obligasi kewangan semasa tempoh sukar apabila aliran tunai operasi berulang tidak mencukupi.Read more

RM 0.3

61.7% undervalued

divine_4y1uv's

Fair Value

Profit Margin

7.23%

Future PE

17.56x

Price in 2031

RM 0.56

Sonic Healthcare

Sonic Healthcare is poised for large upside as margins recover

Sonic Healthcare runs a huge network of medical testing and imaging services, and the key question is whether recent weakness is just a rough patch rather than a lasting problem. If demand steadies and cost pressures cool, profits could rebound even without rapid sales growth—but debt levels and healthcare payment rules remain important watch‑outs.Read more

AU$27

23.0% undervalued

danmad's

Fair Value

Revenue

19.81% p.a.

Profit Margin

5.18%

Future PE

19.35x

Price in 2029

AU$33.35

AmanahRaya Real Estate Investment Trust

Income Focused ARREIT

Amanah Raya REIT shows signs of renewed investor interest after a long slump, helped by a return to profit and steadier demand for commercial property. The catch is that trading is thin and the wider REIT sector still faces cost pressure and uneven recovery, which could cap gains and raise the downside if sentiment turns.Read more

RM 0.21

90.5% overvalued

Ontological's

Fair Value

Revenue

-2.44% p.a.

Profit Margin

11.27%

Future PE

25.99x

Price in 2031

RM 0.38

Qualitas

This company finances 1 out of 10 apartment builds in Australia. Many investors have never heard of it

Key Points: Qualitas (ASX:QAL) is an Australian alternative asset manager that lends to and invests in commercial real estate , standing in for the banks that have quietly halved their share of that lending since 2009. It’s grown extremely fast.Read more

AU$4.24

27.1% undervalued

Ceazar's

Fair Value

Analyst consensus price target as of July 17, 2026.

DuChemBIOLtd

DuChemBio absorbs Radio DNS Labs as Novartis injects 140B KRW into Korean RLT. With 100%+ OCF/EBITDA, the 6-mo lag is a de-risked steal.

DuChemBio (KOSDAQ: 176750): Radiopharmaceutical Monopoly, Radio DNS Labs Merger, and the 6-Month RLT Time Lag 1. The Narrative Origin: From Diagnostic Monopoly to Novartis-Driven RLT Powerhouse DuChemBio is South Korea’s undisputed leader in radiopharmaceuticals.Read more

₩10k

43.5% undervalued

AnimalDoctorKwon's

Fair Value

Revenue

20.6% p.a.

Profit Margin

17.52%

Future PE

22.96x

Price in 2031

₩14.41k

Samsara

Samsara's Future PE Will Soar to 337.7x and the Future is Bright

I can tell you right now that drivers don't want to be spyed on 24/7. RisksO Are there any risks that your catalysts won't play out as expected?Read more